Learn about the latest thinking in HRD testing for ovarian cancer | Webinar Genome Web x SeqOne
With this video, discover new approaches that can reduce the number of inconclusive results and the amount of genomic material needed for your HRD tests.
Watch the cancer geneticist Pr Pascal Pujol, president of the SFMPP (French Society of Personalized and Precision Medicine) and co-founder of the newly formed Joint consensus group on HRD testing and Dr. Michael Blum, head of R&D at SeqOne Genomics, discuss latest developments in HRD testing as well as presenting SeqOne’s newly announced HRD test.
You will learn about:
- Why biomarkers of HRD are effective to predict sensitivity to PARPi maintenance therapy in ovarian cancer
- How to measure HRD – The role of HRR gene panels to measure HRD
- Using algorithmic approaches to determine HRD status
- How SeqOne improves HRD testing : less non-conclusive results, less genetic material needed, faster turnaround time, cost-mitigation and technology agnostic